References
Impact of willingness to accept hepatitis C seropositive kidneys among hepatitis C RNA-positive waitlisted patients. Transplantation. 2018;(102):1179-1187.
. Hepatitis C virus transmission among human immunodeficiency virus-infected men who have sex with men: modeling the effect of behavioral and treatment interventions. Hepatology. 2016;64(6):1856-1869.
. Incidence of hepatitis C virus infection in the human immunodeficiency virus outpatient study cohort, 2000-2013. Open Forum Infect Dis. 2017;4(2):ofx076.
. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology. 2006;43(6):1303-1310.
Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study. J Hepatol. 2012;57(5):946-952.
. Late relapse versus hepatitis C virus reinfection in patients with sustained virologic response after sofosbuvir-based therapies. Clin Infect Dis. 2017;64(1):44-52.
. No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients. J Hepatol. 2018;69(6):1221-1230. doi:10.1016/j.jhep.2018.07.023.
. Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology. 2016;151(3):501-512.E1.
. Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents. Am J Transplant. 2016;16(5):1588-1595.
. Mortality and kidney transplantation outcomes among hepatitis C virus-seropositive maintenance dialysis patients: a retrospective cohort study. Am J Kidney Dis. 2019;73:815-826.
. HCV-TARGET. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 2016;36(6):807-816.
. Safety and efficacy of current DAA regimens in kidney and liver transplant recipients with hepatitis C: results from the HCV-TARGET study. Hepatology. 2017;66(4):1090-1101.
. Dermatologic manifestations of chronic hepatitis C infection. Clin Liver Dis. 2017;21(3):555-564.
. Shorter waitlist times and improved graft survivals are observed in patients who accept hepatitis C virus+ renal allografts. Transplantation. 2015;99:1192-1196.
Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. Addiction. 2015;110(1):129-143. doi:10.1111/add.12754.
. Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs. Drug Alcohol Depend. 2018;(185):411-420.
. Implementation and preliminary results of an emergency department nontargeted, opt-out hepatitis C virus screening program. Acad Emerg Med. 2018;25(11):1226. doi:10.1111/acem.13484.
. CDC recommendations for hepatitis C screening among adults - United States, 2020. MMWR Recomm Rep. 2020;69(2):1-17.
. Expanding heart transplant in the era of direct-acting antiviral therapy for hepatitis C. JAMA Cardiol. 2020;5(2):167-174. doi:10.1001/jamacardio.2019.4748.
.